Hyderabad Latest News: Bharat Biotech and Alopexx Inc Collaborate on AMR Vaccine
Vaccine Development Collaboration
Hyderabad: Bharat Biotech has entered into a collaboration with US-based clinical stage biotech player Alopexx Inc for co-developing and commercialising AV0328, Alopexx's proprietary broad-spectrum anti-microbial vaccine in India and other low-income and lower middle-income countries.
About AV0328
The two companies will collaborate on the synthetic vaccine that targets poly N-acetyl glucosamine (PNAG) in India and other licensed territories. PNAG is a substance found on the surface of a wide range of bacterial, fungal, and parasitic pathogens.
Financial Aspects of the Collaboration
- As part of the deal, Alopexx would be entitled to a one-time upfront payment and milestone payments.
- Additionally, Alopexx will receive royalties on future sales of AV0328 in the licensed territories.
- However, the two companies did not divulge the financial terms of the deal.
Vaccine Efficacy
According to Bharat Biotech, in pre-clinical studies targeting PNAG, the vaccine showed effectiveness in preventing and treating infections caused by over 15 different pathogens.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.